Results 81 to 90 of about 29,714 (227)

Left ventricular remodeling in hypertrophic cardiomyopathy patients with atrial fibrillation

open access: yesBMC Cardiovascular Disorders, 2018
Background Atrial fibrillation (AF) is the most common complication in hypertrophic cardiomyopathy (HCM). The mechanisms of AF is associated with left atrial (LA) structural remodeling in HCM patients.
Hongwei Tian   +8 more
doaj   +1 more source

vanrooij-lab/scRNAseq-HCM-human: v 1.0

open access: yes, 2022
This version of the scripts was used to analyse the data for the publication "Single-cell transcriptomics provides insights into hypertrophic cardiomyopathy" by Wehrens et al. published in Cell Reports (2022)
Martijn Wehrens
core   +1 more source

Coronary Flow in Hypertrophic Obstructive Cardiomyopathy—Immediate Effects of Alcohol Septal Ablation

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Hypertrophic cardiomyopathy is associated with alterations in coronary microvascular function which have variable pathophysiologic mechanisms, and variable reversibility acutely and chronically following alcohol septal ablation (ASA).
Vojko V. Misevic   +12 more
wiley   +1 more source

Investigations into the Sarcomeric Protein and Ca2+-Regulation Abnormalities Underlying Hypertrophic Cardiomyopathy in Cats (Felix catus)

open access: yesFrontiers in Physiology, 2017
Hypertrophic cardiomyopathy (HCM) is the most common single gene inherited cardiomyopathy. In cats (Felix catus) HCM is even more prevalent and affects 16% of the outbred population and up to 26% in pedigree breeds such as Maine Coon and Ragdoll ...
Andrew E. Messer   +5 more
doaj   +1 more source

Carbon Anodes for Low‐Temperature Nonaqueous Alkali Metal‐Ion Batteries

open access: yesEcoEnergy, EarlyView.
This review summarizes recent progress in carbon anodes for low‐temperature nonaqueous alkali‐metal ion batteries. Fundamental thermodynamic and kinetic limitations are examined, alongside a systematic discussion of graphite, hard carbon, and emerging carbon architectures.
Zhichun Miao   +11 more
wiley   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya   +9 more
wiley   +1 more source

Cervical pessary for preterm-birth prevention among pregnant women with a short cervix: A prospective cohort study

open access: yesTaiwanese Journal of Obstetrics & Gynecology
Objective: Congenital abnormalities or secondary factors are reasons for cervical insufficiency. The Arabin pessary has been widely adopted in several countries to manage the condition. However, its usage has yet to be prevalent in Vietnam.
Thoai Ngoc Nguyen   +4 more
doaj   +1 more source

Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li   +12 more
wiley   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant   +17 more
wiley   +1 more source

A phenomap of TTR amyloidosis to aid diagnostic screening

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy